\n| \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n September 30,<\/b><\/p>\n 2025<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n September 30,<\/b><\/p>\n 2025<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Financial Results<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nNet revenue (1)<\/sup><\/p>\n<\/td>\n| \n \n86,021<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n78,809<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n153,575<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n152,885<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nMedical cannabis net revenue (2)<\/sup><\/p>\n<\/td>\n| \n \n82,519<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n70,530<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n146,555<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n135,298<\/p>\n<\/td>\n<\/tr>\n | \n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nGross profit<\/p>\n<\/td>\n | \n \n37,548<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n31,144<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n73,170<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n64,672<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nGross profit before fair value (\u201cFV\u201d) adjustments (1)<\/sup><\/p>\n<\/td>\n| \n \n43,904<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n36,599<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n73,096<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n75,448<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nGross margin (3)<\/sup><\/p>\n<\/td>\n| \n \n44%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n40%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n48%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n42%<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nGross margin before FV adjustments (3)<\/sup><\/p>\n<\/td>\n| \n \n51%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n46%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n48%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n49%<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAdjusted gross margin before FV adjustments on total net revenue (4)<\/sup><\/p>\n<\/td>\n| \n \n61%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n65%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n60%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n65%<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAdjusted gross margin before FV adjustments on medical cannabis net revenue (4)<\/sup><\/p>\n<\/td>\n| \n \n62%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n69%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n62%<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n69%<\/p>\n<\/td>\n<\/tr>\n | \n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nOperating expenses<\/p>\n<\/td>\n | \n \n55,482<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n48,171<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n99,835<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n93,641<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nGeneral and administration<\/p>\n<\/td>\n | \n \n30,267<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n26,294<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n54,869<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n53,166<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nSales and marketing<\/p>\n<\/td>\n | \n \n17,843<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n14,304<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n33,434<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n28,759<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAdjusted selling, general & administration expense (\u201cadjusted SG&A\u201d) (4)<\/sup><\/p>\n<\/td>\n| \n \n37,386<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n34,890<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n72,470<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n70,985<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nOther income (expenses)<\/p>\n<\/td>\n | \n \n(1,563)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(7,550)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n3,538<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(5,865)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nNet loss from continuing operations<\/p>\n<\/td>\n | \n \n(21,050)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(27,182)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(25,083)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(37,368)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nNet loss from discontinued operations, net of tax<\/p>\n<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(25,867)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(35,546)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nNet loss<\/p>\n<\/td>\n | \n \n(21,050)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(53,049)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(25,083)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(72,914)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAdjusted EBITDA (4)<\/sup><\/p>\n<\/td>\n| \n \n13,997<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n15,395<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n17,440<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n26,210<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAdjusted net income (4)<\/sup><\/p>\n<\/td>\n| \n \n3,106<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n11,954<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n6,917<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n18,552<\/p>\n<\/td>\n<\/tr>\n | \n| \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nNet cash used in operating activities from continuing operations<\/p>\n<\/td>\n | \n \n(14,946)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(38,008)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(19,392)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(30,329)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nFree cash flow (4)<\/sup><\/p>\n<\/td>\n| \n \n(17,533)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(39,908)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(23,326)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(33,136)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\n| \n (1)<\/sup><\/p>\n<\/td>\n| \n \n\u00a0<\/p>\n<\/td>\n | \n \nAs presented in the interim condensed consolidated statements of loss and comprehensive loss.<\/p>\n<\/td>\n<\/tr>\n | \n| \n (2)<\/sup><\/p>\n<\/td>\n| \n \n\u00a0<\/p>\n<\/td>\n | \n \nSee \u201cNet Revenue<\/i>\u201d section below.<\/p>\n<\/td>\n<\/tr>\n\n| \n (3)<\/sup><\/p>\n<\/td>\n| \n \n\u00a0<\/p>\n<\/td>\n | \n \nGross margin and Gross margin before FV adjustments, respectively, are calculated as gross profit and gross profit before FV adjustments, respectively, divided by net revenue.<\/p>\n<\/td>\n<\/tr>\n | \n| \n (4)<\/sup><\/p>\n<\/td>\n| \n \n\u00a0<\/p>\n<\/td>\n | \n \nThese terms are defined in the \u201cCautionary Statement Regarding Certain Non-GAAP Performance Measures<\/i>\u201d section in the MD&A. Refer to the respective financial tables herein for a reconciliation to the nearest GAAP measure.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n About Aurora Cannabis<\/b><\/p>\n \nAurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora\u00ae, MedReleaf\u00ae, Pedanios\u00ae, IndiMed\u2122, San Raf\u00ae, and Whistler Medical Marijuana Corporation\u00ae. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis\u2122.<\/p>\n \nAurora\u2019s common shares trade on the NASDAQ and TSX under the symbol \u201cACB\u201d.<\/p>\n Forward Looking Statements<\/b><\/p>\n \nThis news release includes statements containing certain \u201cforward-looking information\u201d within the meaning of applicable securities law (\u201cforward-looking statements\u201d). Forward-looking statements are frequently characterized by words such as \u201cplan\u201d, \u201ccontinue\u201d, \u201cexpect\u201d, \u201cproject\u201d, \u201cintend\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cestimate\u201d, \u201cmay\u201d, \u201cwill\u201d, \u201cpotential\u201d, \u201cproposed\u201d and other similar words, or statements that certain events or conditions \u201cmay\u201d or \u201cwill\u201d occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company\u2019s fiscal 2027 second quarter results and statements regarding the Transaction, including required approvals, filing of the Joint Circular, and anticipated timing for the Special Meeting and completion.<\/p>\n \nThese forward-looking statements are only predictions. Forward-looking information or statements contained in this news release have been developed based on the Company and its management\u2019s good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company\u2019s business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: the Transaction, including satisfaction of conditions to closing, receipt of required approvals, and the Arrangement Agreement not being terminated in accordance with its terms; development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company\u2019s operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company\u2019s operations; and the Company\u2019s ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company\u2019s business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company\u2019s control. Such forward-looking statements are estimates reflecting the Company\u2019s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management\u2019s estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management\u2019s estimation that SG&A will grow only in proportion to revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crisis, and other risks as set out under the heading \u201cRisk Factors\u201d in the Company\u2019s annual information form dated June 10, 2026 (the \u201cAIF\u201d) and filed with Canadian securities regulators available on the Company\u2019s issuer profile on SEDAR+ at www.sedarplus.ca<\/a> and filed with and available on the SEC\u2019s website at www.sec.gov<\/a>. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.<\/p>\nNon-GAAP Measures<\/b><\/p>\n \nThis news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed \u201cNon-GAAP Measures\u201d). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company\u2019s operating results, underlying performance and prospects in a manner similar to Aurora\u2019s management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading \u201cCautionary Statement Regarding Certain Non-GAAP Performance Measures\u201d in the FY27 Q2 MD&A is incorporated by reference into this news release. The MD&A is available on the Company\u2019s issuer profiles on SEDAR+ at www.sedarplus.ca<\/a> and on the U.S. Securities and Exchange Commission\u2019s (the \u201cSEC\u201d) EDGAR website at www.sec.gov<\/a>.<\/p>\nNet Revenue<\/b><\/p>\n \nNet revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:<\/p>\n \n\n| \n ($ thousands)<\/b><\/p>\n<\/td>\n | \n Three months ended<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n Six months ended<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2025<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2025<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \nMedical cannabis net revenue:<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nCanadian medical cannabis net revenue<\/p>\n<\/td>\n | \n \n21,161<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n27,879<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n41,860<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n55,553<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nInternational medical cannabis net revenue<\/p>\n<\/td>\n | \n \n61,358<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n42,651<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n104,695<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n79,745<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nTotal medical cannabis net revenue<\/p>\n<\/td>\n | \n \n82,519<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n70,530<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n146,555<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n135,298<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nConsumer cannabis net revenue<\/p>\n<\/td>\n | \n \n1,631<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n6,868<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n3,691<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n14,743<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nWholesale bulk cannabis net revenue<\/p>\n<\/td>\n | \n \n1,871<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n1,411<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n3,329<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n2,844<\/p>\n<\/td>\n<\/tr>\n | \n| \n Total net revenue (1)<\/sup><\/b><\/p>\n<\/td>\n| \n 86,021<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 78,809<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 153,575<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 152,885<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n| \n (1)<\/sup><\/p>\n<\/td>\n| \u00a0<\/td>\n | \n \nAs presented in the interim condensed consolidated statements of loss and comprehensive loss.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Adjusted EBITDA<\/b><\/p>\n \nThe following is the Company\u2019s adjusted EBITDA:<\/p>\n \n\n| \n ($ thousands)<\/b><\/p>\n<\/td>\n | \n Three months ended<\/b><\/p>\n<\/td>\n | \n Six months ended<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2025 (3)<\/sup><\/b><\/p>\n<\/td>\n| \u00a0<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2025 (3)<\/sup><\/b><\/p>\n<\/td>\n| \u00a0<\/td>\n<\/tr>\n | \n| \n \nNet loss from continuing operations<\/p>\n<\/td>\n | \n \n(21,050<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(27,182<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(25,083<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(37,368<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nIncome tax expense<\/p>\n<\/td>\n | \n \n1,553<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n2,605<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n1,956<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n2,534<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nOther (income) expense<\/p>\n<\/td>\n | \n \n1,563<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n7,550<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(3,538<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n5,865<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nShare-based compensation<\/p>\n<\/td>\n | \n \n3,640<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n4,969<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n4,333<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n7,155<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nDepreciation and amortization<\/p>\n<\/td>\n | \n \n3,946<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n4,215<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n7,373<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n7,775<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nBusiness development costs<\/p>\n<\/td>\n | \n \n1,713<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n321<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n3,302<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n682<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nInventory and biological assets fair value and impairment adjustments<\/p>\n<\/td>\n | \n \n11,908<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n17,209<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n13,264<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n28,627<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nBusiness transformation costs (1)<\/sup><\/p>\n<\/td>\n| \n \n10,724<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n5,708<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n15,833<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n10,940<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n Adjusted EBITDA (2)<\/sup><\/b><\/p>\n<\/td>\n| \n 13,997<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 15,395<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 17,440<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 26,210<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\n| \n (1)<\/sup><\/p>\n<\/td>\n| \u00a0<\/td>\n | \n \nBusiness transformation related charges include costs related to restructuring, certain IT project costs, net sublease income (expenses), severance and retention costs in connection with the consumer channel exit, legal provisions, professional fees incurred in connection with an Hostile Bid and Transaction, and other business transformation initiatives.<\/p>\n<\/td>\n<\/tr>\n | \n(2)<\/sup><\/td>\n | \n\n \nAdjusted EBITDA is defined in the \u201cCautionary Statement Regarding Certain Non-GAAP Performance Measures<\/i>\u201d section of the MD&A. The reconciliation to the most directly comparable IFRS measure has been provided accordingly.<\/p>\n<\/td>\n<\/tr>\n\n(3)<\/sup><\/td>\n | \nPrior period comparatives were adjusted to include the adjustments for non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation.<\/td>\n<\/tr>\n<\/table>\n Adjusted Net Income<\/b><\/p>\n \nThe following is the Company\u2019s adjusted net income:<\/p>\n \n\n| \n ($ thousands)<\/b><\/p>\n<\/td>\n | \n Three months ended<\/b><\/p>\n<\/td>\n | \n Six months ended<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n September 30,<\/b><\/p>\n 2025 (3)<\/sup><\/b><\/p>\n<\/td>\n| \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n September 30,<\/b><\/p>\n 2025 (3)<\/sup><\/b><\/p>\n<\/td>\n| \u00a0<\/td>\n<\/tr>\n | \n| \n \nNet loss from continuing operations<\/p>\n<\/td>\n | \n \n(21,050<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(27,182<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(25,083<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(37,368<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nInventory and biological assets fair value and impairment adjustments<\/p>\n<\/td>\n | \n \n11,908<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n17,209<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n13,264<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n28,627<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nBusiness development costs<\/p>\n<\/td>\n | \n \n1,713<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n321<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n3,302<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n682<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nImpairment of property, plant and equipment<\/p>\n<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n525<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n525<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nImpairment of intangible assets and goodwill<\/p>\n<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n13,186<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n13,186<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nDeferred tax expense – valuation allowance on deferred tax assets<\/p>\n<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n2,359<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n2,359<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nBusiness transformation costs (1)<\/sup><\/p>\n<\/td>\n| \n \n10,535<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n5,536<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n15,434<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n10,541<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n Adjusted net income (2)<\/sup><\/b><\/p>\n<\/td>\n| \n 3,106<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 11,954<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 6,917<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 18,552<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\n| \n (1)<\/sup><\/p>\n<\/td>\n| \u00a0<\/td>\n | \n \nBusiness transformation related charges include costs related to restructuring, certain IT project costs, severance and retention costs in connection with the consumer channel exit, legal provisions, professional fees incurred in connection with the Hostile Bid and Transaction, and other business transformation initiatives.<\/p>\n<\/td>\n<\/tr>\n | \n| \n (2)<\/sup><\/p>\n<\/td>\n | \n\n \nAdjusted net income is defined in the \u201cCautionary Statement Regarding Certain Non-GAAP Performance Measures<\/i>\u201d section of the MD&A. The reconciliation to the most directly comparable IFRS measure has been provided accordingly.<\/p>\n<\/td>\n<\/tr>\n\n| \n (3)<\/sup><\/p>\n<\/td>\n | \n\n \nComparatives were adjusted to include the adjustments for non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Adjusted SG&A<\/b><\/p>\n \nAdjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows:<\/p>\n \n\n| \n \n\u00a0<\/p>\n<\/td>\n | \n Three months ended<\/b><\/p>\n<\/td>\n | \n Six months ended<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n ($ thousands)<\/b><\/p>\n<\/td>\n | \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2025 (3)<\/sup><\/b><\/p>\n<\/td>\n| \u00a0<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2026<\/b><\/p>\n<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \n September 30,<\/b><\/p>\n 2025 (3)<\/sup><\/b><\/p>\n<\/td>\n| \u00a0<\/td>\n<\/tr>\n | \n| \n \nGeneral and administration<\/p>\n<\/td>\n | \n \n30,267<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n26,294<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n54,869<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n53,166<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nSales and marketing<\/p>\n<\/td>\n | \n \n17,843<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n14,304<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n33,434<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n28,759<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nBusiness transformation costs (1)<\/sup><\/p>\n<\/td>\n| \n \n(10,724<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(5,708<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(15,833<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \n(10,940<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| \n Adjusted SG&A (2)<\/sup><\/b><\/p>\n<\/td>\n| \n 37,386<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 34,890<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 72,470<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n 70,985<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\n| \n (1)<\/sup><\/p>\n<\/td>\n| \u00a0<\/td>\n | \n \nBusiness transformation related charges include costs related to restructuring, certain IT project costs, net sublease income (expenses), severance and retention costs in connection with the consumer channel exit, legal provisions, professional fees incurred in connection with the Hostile Bid and Transaction, and other business transformation initiatives.<\/p>\n<\/td>\n<\/tr>\n | \n| \n (2)<\/sup><\/p>\n<\/td>\n | \n\n | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |